M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover Pharmaceutical TechnologyThis acquisition marks Eli Lilly's first move into the psychedelic space as the pharma curates a diversified pipeline.NeuroscienceRead full story pharminent July 16, 2026 (Last updated: July 17, 2026) Pharmaceutical Technology This acquisition marks Eli Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorNext: FDA Approves At-Home Leqembi for Early Alzheimer’s Disease Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
